LINCOLN, Neb., May 02, 2017 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ:NRCIA) and (NASDAQ:NRCIB) today announced results for the first quarter of 2017.
- Net New Sales $4.9 million
- Total Contract Value $119.6 million
- Revenue up 9% to $30.3 million
- Net Income up 18% to $6.5 million
Remarking on Company performance, Michael D. Hays, chief executive officer of National Research Corporation said, “Our first quarter performance was mixed. Revenue and net income growth were positive while we fell short on our target for Net New Sales.”
Revenue for the quarter ended March 31, 2017, was $30.3 million, compared to $27.9 million for the same quarter in 2016. Net income for the quarter ended March 31, 2017, was $6.5 million, compared to $5.5 million for the quarter ended March 31, 2016. Diluted earnings per share increased to $0.15 for Class A shares and $0.91 for Class B shares for the quarter ended March 31 2017, from diluted earnings per share of $0.13 for Class A shares and $0.77 for Class B shares for the quarter ended March 31, 2016. Combined diluted earnings per share (a non-GAAP measure) increased to $0.26 for the quarter ended March 31, 2017, from $0.22 for the first quarter of 2016.
Regarding first quarter performance, Kevin Karas, chief financial officer of National Research Corporation, said, “Both record revenue and net income results were achieved in the first quarter of 2017 as we were able to continue our positive revenue growth trend and leverage that growth to expand operating margin.”
A listen-only simulcast of National Research Corporation’s 2017 first quarter conference call will be available online at http://edge.media-server.com/m/p/e8x7g72o on May 3, 2017, beginning at 11:00 a.m. Eastern time. The online replay will follow approximately one hour later and continue for 30 days.
For more than 36 years, National Research Corporation has been a leading provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers and other healthcare organizations in the United States and Canada. The Company’s solutions enable its clients to understand the voice of the customer with greater clarity, immediacy and depth.
The information discussed within this release includes financial results and projections that are in accordance with accounting principles generally accepted in the United States (GAAP). In addition, certain non-GAAP financial measures have been provided that calculate combined earnings per share based on combined Class A and Class B shares and share equivalents outstanding, respectively. The non-GAAP measures should be read in conjunction with the corresponding GAAP measures and should be considered in addition to, and not as an alternative or substitute for, the measures prepared in accordance with GAAP. Please note that the Company’s non-GAAP measures may be different than those used by other companies. The additional non-GAAP financial information the Company presents should be considered in conjunction with, and not as a substitute for, the Company’s financial information presented in accordance with GAAP. The non-GAAP financial measures are provided in an effort to provide information that investors may deem relevant to evaluate results from the Company's core business operations and to compare the Company's performance with prior periods. The Company uses both GAAP and these non-GAAP financial measures for evaluating comparable financial performance against prior periods.
This press release includes “forward-looking” statements related to the Company that can generally be identified as describing the Company’s future plans, objectives or goals. Such forward-looking statements are subject to risks and uncertainties that could cause actual results or outcomes to differ materially from those currently anticipated. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For further information about the factors that could affect the Company’s future results, please see the Company’s filings with the Securities and Exchange Commission.
| NATIONAL RESEARCH CORPORATION AND SUBSIDIARY Unaudited Condensed Consolidated Statements of Income (In thousands, except per share data) | |||||||
| Three months ended March 31, | |||||||
| 2017 | 2016 | ||||||
| Revenue | $ | 30,276 | $ | 27,870 | |||
| Operating expenses: | |||||||
| Direct | 12,500 | 11,539 | |||||
| Selling, general and administrative | 6,686 | 7,357 | |||||
| Depreciation and amortization | 1,106 | 968 | |||||
| Total operating expenses | 20,292 | 19,864 | |||||
| Operating income | 9,984 | 8,006 | |||||
| Other income (expense): | |||||||
| Interest income | 14 | 11 | |||||
| Interest expense | (27 | ) | (85 | ) | |||
| Other, net | 9 | 74 | |||||
| Total other income (expense) | (4 | ) | -- | ||||
| Income before income taxes | 9,980 | 8,006 | |||||
| Provision for income taxes | 3,459 | 2,500 | |||||
| Net income | $ | 6,521 | $ | 5,506 | |||
| Earnings Per Share of Common Stock: | |||||||
| Basic Earnings Per Share: | |||||||
| Class A | $ | 0.15 | $ | 0.13 | |||
| Class B | $ | 0.93 | $ | 0.79 | |||
| Diluted Earnings Per Share: | |||||||
| Class A | $ | 0.15 | $ | 0.13 | |||
| Class B | $ | 0.91 | $ | 0.77 | |||
| Weighted average shares and share equivalents outstanding | |||||||
| Class A - Basic | 20,737 | 20,710 | |||||
| Class B - Basic | 3,513 | 3,489 | |||||
| Class A - Diluted | 21,245 | 21,012 | |||||
| Class B - Diluted | 3,576 | 3,549 | |||||
| NATIONAL RESEARCH CORPORATION AND SUBSIDIARY | ||||||||
| Unaudited Condensed Consolidated Balance Sheets | ||||||||
| (Dollars in thousands, except per share amounts and par value) | ||||||||
| Mar. 31, | Dec. 31, | |||||||
| 2017 | 2016 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 34,664 | $ | 33,021 | ||||
| Accounts receivable, net | 13,524 | 10,864 | ||||||
| Income taxes receivable | 24 | 14 | ||||||
| Other current assets | 4,171 | 3,166 | ||||||
| Total Current Assets | 52,383 | 47,065 | ||||||
| Property and equipment, net | 12,133 | 11,806 | ||||||
| Goodwill | 57,881 | 57,861 | ||||||
| Other, net | 3,662 | 3,892 | ||||||
| Total Assets | $ | 126,059 | $ | 120,624 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | 3,576 | $ | 3,916 | ||||
| Deferred revenue | 17,189 | 15,497 | ||||||
| Accrued compensation | 3,306 | 4,543 | ||||||
| Dividends payable | 4,218 | 4,213 | ||||||
| Income taxes payable | 3,563 | 662 | ||||||
| Notes payable | 2,499 | 2,683 | ||||||
| Total Current Liabilities | 34,351 | 31,514 | ||||||
| Non-Current Liabilities | 6,136 | 6,304 | ||||||
| Total Liabilities | 40,487 | 37,818 | ||||||
| Shareholders’ Equity: | ||||||||
| Preferred stock, $0.01 par value, authorized 2,000,000 shares, none issued | -- | -- | ||||||
| Class A Common stock, $0.001 par value; authorized 60,000,000 shares, issued 25,753,828 in 2017 and 25,656,760 in 2016, outstanding 20,916,570 in 2017 and 20,891,069 in 2016 | 26 | 26 | ||||||
| Class B Common stock, $0.001 par value; authorized 80,000,000 shares, issued 4,320,875 in 2017 and 4,308,875 in 2016, outstanding 3,543,463 in 2017 and 3,539,931 in 2016 | 4 | 4 | ||||||
| Additional paid-in capital | 48,787 | 46,725 | ||||||
| Retained earnings | 73,810 | 71,507 | ||||||
| Accumulated other comprehensive loss | (2,508 | ) | (2,626 | ) | ||||
| Treasury stock | (34,547 | ) | (32,830 | ) | ||||
| Total Shareholders’ Equity | 85,572 | 82,806 | ||||||
| Total Liabilities and Shareholders’ Equity | $ | 126,059 | $ | 120,624 | ||||
| NATIONAL RESEARCH CORPORATION AND SUBSIDIARY Unaudited Non-GAAP Combined Earnings Per Share Schedule (In thousands, except per share data) | ||||||
| Three months ended March 31, | ||||||
| 2017 | 2016 | |||||
Combined Earnings Per Share (1) | ||||||
| Basic Earnings Per Share | $ | 0.27 | $ | 0.23 | ||
| Diluted Earnings Per Share | $ | 0.26 | $ | 0.22 | ||
| Combined weighted average shares and share equivalents outstanding (2) | ||||||
| Combined - Basic | 24,250 | 24,198 | ||||
| Combined - Diluted | 24,821 | 24,561 | ||||
| (1) | Combined net income attributable to Class A and Class B common shareholders divided by combined weighted average shares and share equivalents outstanding. |
| (2) | Represents the sum of the Class A and Class B weighted average shares and share equivalents outstanding reported in accordance with GAAP. |